



## Clinical trial results:

### A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis

#### Summary

EudraCT number	2016-003046-87
Trial protocol	AT SE BE DE FI CZ PL PT ES FR
Global end of trial date	30 November 2023

#### Results information

Result version number	v1 (current)
This version publication date	06 December 2024
First version publication date	06 December 2024

#### Trial information

##### Trial identification

Sponsor protocol code	M15-997
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03047395
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co. KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB
Public contact	Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>
Scientific contact	Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 November 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 November 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of Study M15-997 is to investigate long-term safety and tolerability of risankizumab in subjects with psoriasis who have completed one of the preceding Phase 2/3 studies.

Protection of trial subjects:

Subject and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 February 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 61
Country: Number of subjects enrolled	Austria: 13
Country: Number of subjects enrolled	Belgium: 13
Country: Number of subjects enrolled	Canada: 432
Country: Number of subjects enrolled	Czechia: 38
Country: Number of subjects enrolled	Finland: 8
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 256
Country: Number of subjects enrolled	Japan: 217
Country: Number of subjects enrolled	Korea, Republic of: 94
Country: Number of subjects enrolled	Mexico: 39
Country: Number of subjects enrolled	Poland: 86
Country: Number of subjects enrolled	Portugal: 19
Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	Sweden: 7
Country: Number of subjects enrolled	Taiwan: 51
Country: Number of subjects enrolled	United States: 815
Worldwide total number of subjects	2170
EEA total number of subjects	461

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1922
From 65 to 84 years	247
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

Participants from Studies M16-008, M16-010, M15-995, M16-178, M16-009, M15-992, and M16-004 entered this open-label extension (OLE) study from 232 sites across 17 countries (Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Japan, Mexico, Poland, Portugal, Republic of Korea, Spain, Sweden, Taiwan, US).

### Pre-assignment

Screening details:

Participants were eligible for study enrollment if he/she met all inclusion criteria and none of the exclusion criteria at the Baseline visit.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Risankizumab 150 mg
------------------	---------------------

Arm description:

Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Risankizumab
Investigational medicinal product code	ABBV-066
Other name	Skyrizi, BI 655066
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.

<b>Number of subjects in period 1</b>	Risankizumab 150 mg
Started	2170
Completed	1601
Not completed	569
Consent withdrawn by subject	155
Other, not specified	117
Adverse event	142
COVID-19 logistical restrictions	9
Lost to follow-up	144
COVID-19 infection	2



## Baseline characteristics

### Reporting groups

Reporting group title	Risankizumab 150 mg
-----------------------	---------------------

Reporting group description:

Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.

Reporting group values	Risankizumab 150 mg	Total	
Number of subjects	2170	2170	
Age categorical			
Units: Subjects			
< 40 years	658	658	
40 - < 65 years	1264	1264	
>= 65 years	248	248	
Gender categorical			
Units: Subjects			
Female	634	634	
Male	1536	1536	
Ethnicity			
Units: Subjects			
Hispanic or Latino	257	257	
Not Hispanic or Latino	1913	1913	
Race			
Units: Subjects			
American Indian or Alaska Native	15	15	
Asian	466	466	
Native Hawaiian or Other Pacific Islander	9	9	
Black or African American	50	50	
White	1622	1622	
More than one race	8	8	

## End points

### End points reporting groups

Reporting group title	Risankizumab 150 mg
Reporting group description: Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.	

### Primary: Number of Participants With Serious Adverse Events or Non-Serious Adverse Events

End point title	Number of Participants With Serious Adverse Events or Non-Serious Adverse Events <sup>[1]</sup>
-----------------	---

End point description:

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.

End point type	Primary
----------------	---------

End point timeframe:

Median follow-up time of 1905 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics are presented per protocol.

<b>End point values</b>	Risankizumab 150 mg			
Subject group type	Reporting group			
Number of subjects analysed	2170			
Units: participants				
Serious Adverse Events	435			
Non-serious Adverse Events	1215			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Median follow-up time of 1905 days

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Risankizumab 150mg
-----------------------	--------------------

Reporting group description:

Risankizumab 150 mg administered by subcutaneous injection every 12 weeks

<b>Serious adverse events</b>	Risankizumab 150mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	435 / 2170 (20.05%)		
number of deaths (all causes)	28		
number of deaths resulting from adverse events	28		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) COLORECTAL ADENOCARCINOMA			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
ANAL CANCER			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
BASAL CELL CARCINOMA			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
BILE DUCT CANCER			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

<b>BLADDER CANCER</b>				
subjects affected / exposed	2 / 2170 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
<b>BLADDER TRANSITIONAL CELL CARCINOMA</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>BORDERLINE MUCINOUS TUMOUR OF OVARY</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>BRAIN NEOPLASM MALIGNANT</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>COLON CANCER STAGE 0</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
<b>COLON CANCER METASTATIC</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
<b>CLEAR CELL RENAL CELL CARCINOMA</b>				
subjects affected / exposed	2 / 2170 (0.09%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
<b>CHRONIC LYMPHOCYTIC LEUKAEMIA</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

<b>CHROMOPHOBE RENAL CELL CARCINOMA</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
<b>BREAST CANCER STAGE II</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>BREAST CANCER RECURRENT</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
<b>BREAST CANCER</b>				
subjects affected / exposed	2 / 2170 (0.09%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
<b>ADENOCARCINOMA OF COLON</b>				
subjects affected / exposed	3 / 2170 (0.14%)			
occurrences causally related to treatment / all	2 / 3			
deaths causally related to treatment / all	0 / 0			
<b>INVASIVE LOBULAR BREAST CARCINOMA</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>LARYNGEAL CANCER STAGE II</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>LARYNGEAL SQUAMOUS CELL CARCINOMA</b>				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

LIPOSARCOMA METASTATIC				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
LUNG ADENOCARCINOMA				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
LUNG CANCER METASTATIC				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
LUNG NEOPLASM MALIGNANT				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
COLORECTAL ADENOMA				
subjects affected / exposed	3 / 2170 (0.14%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
COLORECTAL CANCER				
subjects affected / exposed	2 / 2170 (0.09%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
ENDOMETRIAL ADENOCARCINOMA				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
ENDOMETRIAL CANCER STAGE II				
subjects affected / exposed	1 / 2170 (0.05%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
GASTRIC CANCER				

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GERM CELL CANCER METASTATIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GLIOBLASTOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HAEMANGIOMA OF LIVER</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>HEPATIC CANCER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INVASIVE BREAST CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INVASIVE DUCTAL BREAST CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MALIGNANT MELANOMA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>SARCOMA UTERUS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MENINGIOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>METASTATIC SQUAMOUS CELL CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PANCREATIC CARCINOMA</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>PANCREATIC CARCINOMA STAGE IV</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PAPILLARY THYROID CANCER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PENILE SQUAMOUS CELL CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PLASMA CELL MYELOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PROSTATE CANCER</b>			

subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>PROSTATE CANCER METASTATIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PROSTATE CANCER STAGE IV</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RECTAL ADENOCARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RECTAL CANCER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RENAL CANCER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RENAL CELL CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MALIGNANT MELANOMA IN SITU</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>UTERINE CANCER</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TRANSITIONAL CELL CARCINOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SUPERFICIAL SPREADING MELANOMA STAGE I</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SQUAMOUS CELL CARCINOMA OF THE TONGUE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SQUAMOUS CELL CARCINOMA OF SKIN</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>SCHWANNOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UTERINE LEIOMYOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

UTERINE MYOMA EXPULSION			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
TRIPLE NEGATIVE BREAST CANCER			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
HYPERTENSIVE URGENCY			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HYPERTENSION			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
EMBOLISM ARTERIAL			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
AORTIC ANEURYSM			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
AORTIC STENOSIS			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ARTERIOSCLEROSIS			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
DEEP VEIN THROMBOSIS			

subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>VARICOSE VEIN</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PELVIC VENOUS THROMBOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VASCULAR STENOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Surgical and medical procedures</b>			
<b>ABDOMINOPLASTY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ABORTION INDUCED</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>Pregnancy, puerperium and perinatal conditions</b>			
<b>ECLAMPSIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

ABORTION SPONTANEOUS			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
SURGICAL FAILURE			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DEATH			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 6		
MULTIPLE ORGAN DYSFUNCTION SYNDROME			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PAIN			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SUDDEN CARDIAC DEATH			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

SUDDEN DEATH			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
VASCULAR STENT STENOSIS			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
BALANOPOSTHITIS			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BENIGN PROSTATIC HYPERPLASIA			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BREAST ENLARGEMENT			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CYSTOCELE			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ENDOMETRIAL DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ENDOMETRIOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEAVY MENSTRUAL BLEEDING</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PROSTATITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>PNEUMOTHORAX</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ACUTE RESPIRATORY FAILURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ASTHMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</b>			

subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>COUGH</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DYSPNOEA EXERTIONAL</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NASAL SEPTUM DEVIATION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PNEUMONITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RESPIRATORY DISTRESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PULMONARY EMBOLISM</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
<b>RESPIRATORY FAILURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
COMPLETED SUICIDE			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>CATATONIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>BIPOLAR DISORDER</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ANXIETY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ANOREXIA NERVOSA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ALCOHOL WITHDRAWAL SYNDROME</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ALCOHOL ABUSE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>CONFUSIONAL STATE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DEPRESSED MOOD</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DEPRESSION</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>POST-TRAUMATIC AMNESTIC DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POST-TRAUMATIC STRESS DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SCHIZOPHRENIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SOMATIC SYMPTOM DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SUICIDE ATTEMPT</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hepatobiliary disorders</b>			
<b>AUTOIMMUNE HEPATITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CHOLECYSTITIS</b>			

subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>CHOLECYSTITIS ACUTE</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		
<b>CHOLELITHIASIS</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
<b>CIRRHOSIS ALCOHOLIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GALLBLADDER POLYP</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEPATIC CIRRHOSIS</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
<b>HEPATITIS ALCOHOLIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ALCOHOLIC LIVER DISEASE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Investigations</b>			
<b>BLOOD TRIGLYCERIDES INCREASED</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEPATIC ENZYME INCREASED</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Injury, poisoning and procedural complications</b>			
<b>CARTILAGE INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ACETABULUM FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ALCOHOL POISONING</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ANKLE FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>COLON INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>LIMB INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CONTUSION</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CRANIOCEREBRAL INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CRANIOFACIAL FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>FALL</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
<b>FEMUR FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>FIBULA FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>HAND FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEAD INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HIP FRACTURE</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HUMERUS FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INTENTIONAL OVERDOSE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>JOINT DISLOCATION</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LIGAMENT INJURY</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LIGAMENT RUPTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>CONCUSSION</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LIMB TRAUMATIC AMPUTATION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>LOWER LIMB FRACTURE</b>			

subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LUMBAR VERTEBRAL FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MENISCUS INJURY</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>MULTIPLE INJURIES</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NAIL INJURY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PATELLA FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POST PROCEDURAL COMPLICATION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POST PROCEDURAL HAEMATOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POST PROCEDURAL SWELLING</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RADIUS FRACTURE</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>RIB FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ROAD TRAFFIC ACCIDENT</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>SKIN ABRASION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SPINAL COMPRESSION FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>SUBDURAL HAEMATOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TENDON DISLOCATION</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>TENDON INJURY</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UPPER LIMB FRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ULNA FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>TOXICITY TO VARIOUS AGENTS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TIBIA FRACTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>THERMAL BURN</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TENDON RUPTURE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>WRIST FRACTURE</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Congenital, familial and genetic disorders</b>			
<b>ATRIAL SEPTAL DEFECT</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CONGENITAL CYSTIC KIDNEY DISEASE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HYPERTROPHIC CARDIOMYOPATHY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
<b>AORTIC VALVE INCOMPETENCE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ACUTE MYOCARDIAL INFARCTION</b>			
subjects affected / exposed	13 / 2170 (0.60%)		
occurrences causally related to treatment / all	2 / 13		
deaths causally related to treatment / all	0 / 0		
<b>ANGINA PECTORIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ANGINA UNSTABLE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ACUTE CORONARY SYNDROME</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ARRHYTHMIA</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CORONARY ARTERY OCCLUSION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ATRIAL FIBRILLATION</b>			
subjects affected / exposed	9 / 2170 (0.41%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
<b>ATRIAL FLUTTER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ATRIAL TACHYCARDIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ATRIOVENTRICULAR BLOCK FIRST DEGREE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ATRIOVENTRICULAR BLOCK SECOND DEGREE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>BIFASCICULAR BLOCK</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>BRADYCARDIA</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CARDIAC ARREST</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>CARDIAC FAILURE CONGESTIVE</b>			
subjects affected / exposed	5 / 2170 (0.23%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	1 / 1		
<b>CARDIAC VENTRICULAR THROMBOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CARDIO-RESPIRATORY ARREST</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>CARDIOMYOPATHY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CARDIOVASCULAR DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>CORONARY ARTERY DISEASE</b>			
subjects affected / exposed	9 / 2170 (0.41%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
<b>ARTERIOSCLEROSIS CORONARY ARTERY</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DRESSLER'S SYNDROME</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PERICARDIAL EFFUSION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PERICARDITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PRINZMETAL ANGINA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SINUS NODE DYSFUNCTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SUPRAVENTRICULAR TACHYCARDIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VENTRICULAR EXTRASYSTOLES</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VENTRICULAR FIBRILLATION</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MYOCARDIAL INFARCTION</b>			
subjects affected / exposed	9 / 2170 (0.41%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 2		
<b>Nervous system disorders</b>			
<b>CEREBROVASCULAR ACCIDENT</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>BELL'S PALSY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CAROTID ARTERY STENOSIS</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>CEREBRAL HAEMATOMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CEREBRAL HAEMORRHAGE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	5 / 2170 (0.23%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
<b>ISCHAEMIC STROKE</b>			

subjects affected / exposed	5 / 2170 (0.23%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		
<b>HYPOAESTHESIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEMIPARESIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HEADACHE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HAEMORRHAGIC STROKE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>EPILEPSY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DIZZINESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DEMENTIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>METABOLIC ENCEPHALOPATHY</b>			

subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>SEIZURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RUPTURED CEREBRAL ANEURYSM</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PROGRESSIVE SUPRANUCLEAR PALSY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PRESYNCOPE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PARTIAL SEIZURES</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PARAESTHESIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NEURALGIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MULTIPLE SCLEROSIS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SENSORY DISTURBANCE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SUBARACHNOID HAEMORRHAGE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SYNCOPE</b>			
subjects affected / exposed	7 / 2170 (0.32%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
<b>THALAMIC INFARCTION</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>TOXIC ENCEPHALOPATHY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TRANSIENT ISCHAEMIC ATTACK</b>			
subjects affected / exposed	5 / 2170 (0.23%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
<b>VERTEBROBASILAR INSUFFICIENCY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>STATUS EPILEPTICUS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>ANAEMIA</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>FEBRILE NEUTROPENIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HAEMOLYSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PANCYTOPENIA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Ear and labyrinth disorders</b>			
<b>SUDDEN HEARING LOSS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VERTIGO</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VERTIGO POSITIONAL</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Eye disorders</b>			

BLINDNESS UNILATERAL			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CATARACT			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
EPIRETINAL MEMBRANE			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
MACULAR HOLE			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
GASTRIC ULCER			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL HERNIA			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL INCARCERATED HERNIA			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ASCITES			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CHRONIC GASTRITIS			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>COLITIS ISCHAEMIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DUODENAL ULCER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DYSPEPSIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GASTRIC ULCER HAEMORRHAGE</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>PANCREATITIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
<b>GASTRITIS EROSIVE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GASTROESOPHAGEAL REFLUX DISEASE</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>HAEMATEMESIS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HAEMATOCHEZIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HAEMORRHOIDS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INCARCERATED INGUINAL HERNIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INCARCERATED UMBILICAL HERNIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INGUINAL HERNIA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>INTESTINAL ISCHAEMIA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LARGE INTESTINE PERFORATION</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>LARGE INTESTINE POLYP</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>OESOPHAGEAL STENOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>OESOPHAGITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GASTRITIS</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>PANCREATITIS ACUTE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RECTAL STENOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RETROPERITONEAL MASS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SMALL INTESTINAL OBSTRUCTION</b>			

subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>TOOTH DISORDER</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UMBILICAL HERNIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UPPER GASTROINTESTINAL HAEMORRHAGE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VOMITING</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RECTAL HAEMORRHAGE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Skin and subcutaneous tissue disorders</b>			
<b>ANGIOEDEMA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ECZEMA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LICHEN PLANUS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PRECANCEROUS SKIN LESION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>STEVENS-JOHNSON SYNDROME</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Renal and urinary disorders</b>			
<b>PYELOCALIECTASIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RENAL ARTERY STENOSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RENAL COLIC</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ACUTE KIDNEY INJURY</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>CALCULUS URINARY</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
<b>CYSTITIS INTERSTITIAL</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HYDRONEPHROSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NEPHROLITHIASIS</b>			
subjects affected / exposed	8 / 2170 (0.37%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
<b>PELVI-URETERIC OBSTRUCTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>RENAL CYST</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Endocrine disorders</b>			
<b>GOITRE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GRAVES' DISEASE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>THYROTOXIC CRISIS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HYPERTHYROIDISM</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Musculoskeletal and connective tissue disorders</b>			
<b>BACK PAIN</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ARTHRALGIA</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>PAIN IN EXTREMITY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>OSTEONECROSIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
<b>OSTEOARTHRITIS</b>			
subjects affected / exposed	17 / 2170 (0.78%)		
occurrences causally related to treatment / all	0 / 20		
deaths causally related to treatment / all	0 / 0		
<b>LUMBAR SPINAL STENOSIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>LOOSE BODY IN JOINT</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INTERVERTEBRAL DISC PROTRUSION</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
<b>FOOT DEFORMITY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CERVICAL SPINAL STENOSIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>PSORIATIC ARTHROPATHY</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TENDINOUS CONTRACTURE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SYSTEMIC LUPUS ERYTHEMATOSUS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SYNOVITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SYNOVIAL CYST</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SPONDYLOLISTHESIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SPINAL STENOSIS</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>SPINAL LIGAMENT OSSIFICATION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ROTATOR CUFF SYNDROME</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>TENOSYNOVITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Infections and infestations</b>			
<b>BRONCHIOLITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ABSCCESS JAW</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ABSCCESS LIMB</b>			

subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>APPENDICITIS</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	2 / 6		
deaths causally related to treatment / all	0 / 0		
<b>ARTHRITIS BACTERIAL</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>BURSITIS INFECTIVE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>INTERVERTEBRAL DISCITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CELLULITIS OF MALE EXTERNAL GENITAL ORGAN</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CHRONIC TONSILLITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CLOSTRIDIUM DIFFICILE COLITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>COVID-19</b>			

subjects affected / exposed	13 / 2170 (0.60%)		
occurrences causally related to treatment / all	3 / 14		
deaths causally related to treatment / all	1 / 5		
<b>COVID-19 PNEUMONIA</b>			
subjects affected / exposed	7 / 2170 (0.32%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 2		
<b>DIVERTICULITIS</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	0 / 0		
<b>EPIDIDYMITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ERYSIPELAS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ESCHERICHIA URINARY TRACT INFECTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>FALLOPIAN TUBE ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>FOURNIER'S GANGRENE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GAS GANGRENE</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>GASTROENTERITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HERPES ZOSTER</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
<b>INFECTIVE GLOSSITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CELLULITIS</b>			
subjects affected / exposed	5 / 2170 (0.23%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		
<b>LARGE INTESTINE INFECTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PSOAS ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MENINGITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NEUROSYPHILIS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>ORCHITIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>OSTEOMYELITIS</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
<b>PERICORONITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PERIRECTAL ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PERITONITIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>PERITONSILLAR ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PNEUMONIA</b>			
subjects affected / exposed	7 / 2170 (0.32%)		
occurrences causally related to treatment / all	3 / 7		
deaths causally related to treatment / all	0 / 0		
<b>PNEUMONIA ASPIRATION</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>PNEUMONIA BACTERIAL</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PNEUMONIA VIRAL</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POST PROCEDURAL INFECTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>POSTOPERATIVE ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PSEUDOMONAL SEPSIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>MEDIASTINAL ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PYELONEPHRITIS</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
<b>RENAL ABSCESS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SCROTAL ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SEPSIS</b>			
subjects affected / exposed	6 / 2170 (0.28%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	0 / 0		
<b>SEPTIC SHOCK</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
<b>STAPHYLOCOCCAL INFECTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>SUBCUTANEOUS ABSCESS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TONSILLITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>URINARY TRACT INFECTION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UROSEPSIS</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>VESTIBULAR NEURONITIS</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>PYELONEPHRITIS ACUTE</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Metabolism and nutrition disorders</b>			
<b>DEHYDRATION</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>DIABETES MELLITUS</b>			
subjects affected / exposed	3 / 2170 (0.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>DIABETIC KETOACIDOSIS</b>			
subjects affected / exposed	2 / 2170 (0.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>ELECTROLYTE IMBALANCE</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HYPERGLYCAEMIA</b>			
subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>HYPOKALAEMIA</b>			

subjects affected / exposed	1 / 2170 (0.05%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>OBESITY</b>			
subjects affected / exposed	4 / 2170 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Risankizumab 150mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1215 / 2170 (55.99%)		
Vascular disorders			
<b>HYPERTENSION</b>			
subjects affected / exposed	227 / 2170 (10.46%)		
occurrences (all)	245		
Nervous system disorders			
<b>HEADACHE</b>			
subjects affected / exposed	134 / 2170 (6.18%)		
occurrences (all)	211		
Musculoskeletal and connective tissue disorders			
<b>BACK PAIN</b>			
subjects affected / exposed	124 / 2170 (5.71%)		
occurrences (all)	142		
<b>ARTHRALGIA</b>			
subjects affected / exposed	217 / 2170 (10.00%)		
occurrences (all)	267		
Infections and infestations			
<b>COVID-19</b>			
subjects affected / exposed	360 / 2170 (16.59%)		
occurrences (all)	384		
<b>NASOPHARYNGITIS</b>			

subjects affected / exposed	480 / 2170 (22.12%)		
occurrences (all)	833		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	312 / 2170 (14.38%)		
occurrences (all)	467		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 December 2016	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Specify primary objective of the study is to investigate long term safety and tolerability of risankizumab in subjects with psoriasis.</li> <li>• Specify secondary objective of the study is to investigate long term efficacy of risankizumab in subjects with psoriasis.</li> <li>• Add Inclusion Criterion 2 from Section 1.1, Synopsis, to Section 5.2.1, Inclusion Criteria.</li> <li>• Clarify Section 5.2.4, Contraception Recommendations and Pregnancy Testing, contraception language regarding methotrexate (MTX).</li> <li>• Add definition of the PASI50 endpoint to Section 5.3.3.2, Additional Variables.</li> <li>• Add the 25th and 75th percentiles to Section 8.1.4, Statistical Analysis of Efficacy.</li> <li>• Add the 95% Confidence Intervals to Section 8.1.4, Statistical Analysis of Efficacy.</li> <li>• Add a detailed description of the pharmacokinetic analysis.</li> <li>• Add details on Use of Information (Section 12.0, Use of Information).</li> <li>• Add details on Data Quality Assurance (Section 11.0, Data Quality Assurance).</li> </ul>
06 June 2017	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Add Study M16-178 as additional preceding study that could enroll subjects in Study M15-997.</li> <li>• Increase expected number of subjects enrolled to 2000.</li> <li>• Add the possibility to have qualified and delegated site staff members to perform the efficacy assessments.</li> <li>• Add "arm" as additional possible injection site.</li> <li>• Update the relationship to study drug definitions.</li> <li>• Add information on Interim Database Lock in Q4 2017.</li> <li>• Correct typographical and grammatical errors throughout the document.</li> </ul>
10 January 2018	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Add Study 1311.13 as additional preceding study that could enroll subjects in Study M15-997.</li> <li>• Update the exception for prohibited topical treatments for psoriasis or any other skin condition.</li> </ul>
21 June 2018	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Extend the period between the last administered dose of risankizumab and the End of Observation Visit from 16 to 20 weeks.</li> <li>• Update the number of subjects to be enrolled to approximately 2200.</li> <li>• Revise inclusion and exclusion criteria to require that women of childbearing potential use contraception throughout the study, including 20 weeks after the last dose of study drug, and exclude subjects who are pregnant, breastfeeding or considering becoming pregnant throughout the study, including 20 weeks after the last dose of study drug.</li> <li>• Add the establishment of an independent external Anaphylaxis Adjudication Committee (AAC).</li> <li>• Add request to draw additional blood samples in case of a suspected systemic post-dose hypersensitivity reaction and conduct additional blood tests in case of a systemic hypersensitivity reaction.</li> <li>• Update the treatment-emergent AE definition to include events until 20 weeks (140 days) after the last risankizumab injection.</li> <li>• Decrease the pharmacokinetic (PK) and anti-drug antibody (ADA) sample collection.</li> <li>• Correct typographical and grammatical errors and make some small clarifying changes throughout the document.</li> </ul>

24 September 2019	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Update the Sponsor/Emergency contact/Primary Therapeutic Area Medical Director</li> <li>• Extend the study duration from 156 weeks to 252 weeks with study visits every 24 weeks after Week 156.</li> <li>• Allow self-administration of risankizumab at home at Weeks 168, 192, 216 and 240 and add corresponding requirements for this.</li> <li>• Update the Introduction and the Benefits and Risks section of the protocol to match the latest Investigator Brochure.</li> <li>• Remove the need to consult with the AbbVie TAMD for use of lower potency topical steroids and define the limited period of time for use being approximately 6 weeks.</li> <li>• Add clearer guidance on when study drug administration may resume after being postponed for a serious infection.</li> <li>• Remove drug storage temperature excursion requirements.</li> <li>• Remove the necessity to retain empty IP boxes and sharps containers at site until the AbbVie monitor is on site to confirm the medication.</li> <li>• Update the definitions of analysis populations.</li> <li>• Remove short-term efficacy summary.</li> <li>• Correct typographical and grammatical errors and make some small clarifying changes throughout the document.</li> </ul>
26 November 2019	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Remove the sentence "In the event that a suspected anaphylactic reaction occurs while the subject is not on site at the study clinic, the treating facility should be advised to perform serum tryptase and histamine to help better understand and characterize the diagnosis." from the section Monitoring for Hypersensitivity Reaction.</li> </ul>
17 November 2020	<p>The purpose of this amendment is to: Incorporate necessary protocol modifications due to the COVID-19 pandemic as follows:</p> <ul style="list-style-type: none"> <li>• Section 1.3 – added COVID-19 Specific Abbreviations</li> <li>• Section 3.2 – included information on the re-evaluation of the benefit and risk to subjects participating in the study.</li> <li>• Section 5.1 – added that study visits may be impacted due to the COVID-19 pandemic.</li> <li>• Section 5.3.1.1 – updated to include details on how to perform specific activities/procedures that may be impacted by changes in global/local regulations due to the pandemic</li> <li>• Section 5.4.1 – included guidance on interruption or discontinuation of study drug due to COVID-19 infection</li> <li>• Section 5.5.4 – included instructions on possible Direct-to patient study drug shipment</li> <li>• Section 6.1.5 – added information on reporting requirements in the eCRF in the event of COVID-19 related missed/virtual visits, study drug interruptions or discontinuation, or adverse events</li> <li>• Section 7.0 – clarified that protocol deviations may include modifications due to COVID-19</li> <li>• Section 10.2 – noted that supplemental study case report form should be completed in the event of COVID-19 related missed/virtual visits, study drug discontinuations, or adverse events and that remote monitoring may be employed as needed.</li> <li>• State that monitoring by the independent Data Monitoring Committee will no longer be in effect for this open-label study.</li> <li>• Clarify which cardiovascular adverse events will be formally adjudicated.</li> <li>• Clarify the discontinuation criteria.</li> <li>• Clarify that following discontinuation of study drug subjects can be treated in accordance with the Investigator's best clinical judgement.</li> <li>• Update the Sponsor/Emergency contact/Primary Therapeutic Area Medical Director.</li> </ul>

18 October 2021	<p>The purpose of this amendment is to:</p> <ul style="list-style-type: none"> <li>• Throughout the protocol, remove the requirement for the physical exam, clinical laboratory samples and efficacy assessments PASI, sPGA, NAPSI, PPASI, PSSI, and the DLQI at the End of Observation (EOO) visit and change the EOO visit from an in-person visit to a phone visit.</li> <li>• Change the End of Observation visit requirement to perform an ECG, TB testing and additional clinical laboratory testing to the EOT visit in Appendix C ("Study Activities Flow Chart").</li> <li>• Clarify the analysis of the immunogenicity samples in Section 5.3.2.4 ("Measurement Methods").</li> <li>• Add INR test to be performed if ALT or AST &gt; 3 x ULN to Table 1 Clinical Laboratory Test in Section 5.3.1.1 ("Study Procedures").</li> <li>• Update the definition of hepatic injury to include marked peak aminotransferase elevations ≥ 8-fold ULN, instead of ≥ 10-fold ULN in Section 6.1.1.3 ("Adverse Events of Special Interests").</li> <li>• Clarify in Section 6.1.1.3 Adverse Events of Special Interests, that the supplemental hepatic eCRFs have to be completed for any hepatic related AE leading to discontinuation or interruption of study drug or any hepatic related SAE, not meeting the hepatic injury definition.</li> <li>• Add language to address potential use of SARS-CoV-2 vaccines to Section 5.2.3 ("Prior and Concomitant Therapy") and Section 6.1.5 ("Adverse Event Reporting").</li> <li>• Update the Sponsor/Emergency contact/Primary Therapeutic Area Medical Director and Alternate Contact for Protocol Deviations in Section 1.0 ("Title Page"), Section 6.1.5 ("Adverse Event Reporting") and Section 7.0 ("Protocol Deviations").</li> </ul>
-----------------	---

Notes:

---

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported